Targeting the programmed cell death-1 pathway in breast and ovarian cancer

Current Opinion in Obstetrics and Gynecology

Volumn 28, Issue 2, 2016, Pages 142-147

  Emens, Leisha A ^a   Kok, Marleen ^b   Ojalvo, Laureen S ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; immune checkpoint blockade; immunotherapy; ovarian cancer

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; BIOLOGICAL MARKER; BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; CANCER IMMUNOTHERAPY; DRUG ACTIVITY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BREAST NEOPLASMS; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; OVARIAN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY; OVARIAN NEOPLASMS;

EID: 84960385383     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000257     Document Type: Review

References (37)

1. Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. Oncology (Williston Park) 2015; 29:375-385.
2. Lipson EJ, Forde PM, Hammers HJ, et al. Antagonists of PD-1 and PD-L1 in cancer treatment. Semin Oncol 2015; 42:587-600.
3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-264.
4. Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol 2016; 47:52-63.
5. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol 2014; 32:2959-2966.
6. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 2015; 33:983-991.
7. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 2014; 25:1544-1550.
8. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumorinfiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013; 31:860-867.
9. Miyashita M, Sasano H, Tamaki K, et al. Prognostic significance of tumorinfiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res 2015; 17:124.
10. Nabholtz JM, Abrial C, Mouret-Reynier MA, et al. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol 2014; 25:1570-1577.
11. Salgado R, Denkert C, Demaria S, et al. Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014. Ann Oncol 2014; 26:259-271.
12. Sun S, Fei X, Mao Y, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother 2014; 63:395-406.
13. Qin T, Zeng YD, Qin G, et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget 2015; 6:33972-33981.
14. Ghebeh H, Barhoush E, Tulbah A, et al. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer 2008; 8:57.
15. Gatalica Z, Snyder C, Maney T, et al. Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type. Cancer Epidemiol Biomarkers Prev 2014; 23:2965-2970.
16. Wimberly H, Brown JR, Schalper K, et al. PD-L1 expression correlates with tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy in breast cancer. Cancer Immunol Res 2015; 3:326-332.
17. Muenst S, Schaerli AR, Gao F, et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2014; 146:15-24.
18. Muenst S, Soysal SD, Gao F, et al. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat 2013; 139:667-676.
19. Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triplenegative breast cancer. Cancer Immunol Res 2014; 2:361-370.
20. Ali HR, Glont SE, Blows FM, et al. PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Ann Oncol 2015; 26:1488-1493.
21. Baptista MZ, Sarian LO, Derchain SF, et al. Prognostic significance of PD-L1 and PD-L2 in breast cancer. Hum Pathol 2016; 47:78-84.
22. Beckers RK, Selinger CI, Vilain R, et al. PDL1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology 2015; epub doi: 10.111/his 12904.
23. Nanda R, Chow LQ, Dees E, et al. A phase Ib study of pembrolizumab in patients with advanced triple negative breast cancer. In: San Antonio Breast Cancer Symposium. San Antonio, Texas; 2014.
24. Rugo H, DeLord JP, Im SA, et al. Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1-positive, ER-positive (ER+)/HER-2 negative breast cancer enrolled in Keynote 028. In: San Antonio Breast Cancer Symposium. San Antonio, Texas; 2015.
25. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PDL1 by MDPL3280A leads to clinical responses in patients with metastatic triple negative breast cancer. In: San Antonio Breast Cancer Symposium. San Antonio, Texas; 2014.
26. Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL13280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). In: AACR. Philadelphia, Pennsylvania; 2015.
27. Dirix LY, Nikolinskos P, Jerusalem G, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor trial. In: San Antonio Breast Cancer Symposium. San Antonio, Texas; 2015.
28. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-213.
29. Darb-Esfahani S, Kunze CA, Kulbe H, et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 2015. [Epub ahead of print]
30. Webb JR, Milne K, Nelson BH. PD-1 and CD103 are widely co-expressed on prognostically favorable intraepithelial CD8 T cells in human ovarian cancer. Cancer Immunol Res 2015; 3:926-935.
31. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104:3360-3365.
32. Abiko K, Matsumura N, Hamanishi J, et al. IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 2015; 112:1501-1509.
33. Hamanishi J, Mandai M, Ikeda T, et al. Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol 2015; 33:4015-4022.
34. Varga A, Piha-Paul SA, Ott PA, et al. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. In: ASCO. Chicago, Illinois; 2015.
35. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366:2455-2465.
36. Disis M, Patel M, Pant S, et al. Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. In: ASCO. Chicago, Illinois; 2015.
37. Adams S, Diamond J, Hamilton E, et al. Safety and clinical activity of atezolizumab (anti-PD-L1) in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer. In: San Antonio Breast Cancer Symposium. San Antonio, Texas; 2015.